In Focus channel feed – Endpoints News

SIGN UP

In focus channel feed

Rich Horgan spearheaded a gene therapy for his brother. The trial ended in tragedy, but the work continues for more patients

4 days ago

Families raised millions and handed rare disease therapies off to biotechs. But companies have backed out

Last week

CAR-T reshaped cancer treatment. Can it change autoimmune disease, too?

Last month

No longer ‘dead or just hibernating,’ drugmakers return to heart medicines

2 months ago

Rare disease trials can't find enough patients. It's forcing the FDA to rethink its approach

2 months ago

‘Harder to find homes’: Latest wave of biotech layoffs could test the industry

2 months ago

A radioactive prostate cancer therapy is a last lifeline for patients. Novartis can't make enough of it

2 months ago

Decades after breakthrough, scientists still puzzling over mRNA delivery

3 months ago

Thousands of gene and cell therapies are inundating FDA reviewers as the agency tries to keep up

3 months ago

How Purdue's $272M addiction payout funded a new home for its discarded non-opioid research

3 months ago

A stem cell pioneer sent an experiment into space. Patients are the next frontier

4 months ago

The conference is back. What about the industry? Taking the biotech pulse at #JPM23

4 months ago

As money pours into digital therapeutics, insurance coverage crawls

5 months ago

Covid-19 spurred a historic vaccine R&D effort. What does it mean for future pandemics?

6 months ago

A biotech paused a gene therapy hatched by families. Now they want control

7 months ago

Father starts lab after intellectual property issues stymie rare disease drug development

7 months ago

Even as pandemic recedes, short-staffed trial sites leave cancer patients waiting

8 months ago

China's DNA giant confronts skepticism in US expansion bid

9 months ago

After years of failures, the hunt for a new type of Parkinson’s drug is on

9 months ago

Biotech's 'sugar high' led to a correction, but winter doldrums could make way for a turnaround story this fall

9 months ago

Biotech’s downturn fuels a billionaire’s niche investment industry

9 months ago

Those big billion-dollar PhIII studies? Martin Landray says they can be done for a tiny fraction of the cost

9 months ago

Why non-opioid pain drugs keep failing — and what's next for the field

9 months ago

An MIT professor's rare disease quest ripples throughout biotech

10 months ago

12 3 4 Next page Last page